NDAORALSOLUTION
Approved
Jan 2025
Lifecycle
Growth
Competitive Pressure
0/100
Mechanism of Action
Dipeptidyl Peptidase 4 Inhibitors
Pharmacologic Class:
Dipeptidyl Peptidase 4 Inhibitor
Indications (1)
Loss of Exclusivity
LOE Date
Oct 23, 2040
178 months away
Patent Expiry
Oct 23, 2040
Company
R-Pharm US
NJ - Princeton